Evidence-based pharmacologic treatment for mild asthma

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1375-1379

  Koh, M S ^a   Irving, L B ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; PREDNISOLONE; THEOPHYLLINE; XANTHINE DERIVATIVE; ZAFIRLUKAST;

ADD ON THERAPY; ASTHMA; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; LUNG FUNCTION; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; LEUKOTRIENE ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447326938     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01410.x     Document Type: Review

References (22)

1. National Asthma Education and Prevention Program, National Heart LaBI, National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma. NIH 97-4051, 1. Asthma Expert Panel Report 2. Bethesda, MD : National Institutes of Health, 1997.
2. Workshop Report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.com (accessed March 2007).
3. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990 336 : 1391 6.
4. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonist and the risk of death and near death from asthma. N Engl J Med 1992 326 : 501 6.
5. Pauwels RA, Pedersen S, Busse WW et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003 361 : 1071 6.
6. Sevinc C, Cimrin AH, Ellidokuz H. Withdrawal of inhaled corticosteroids therapy in long-term, stable, mild to moderate, persistent asthmatic patients. J Investig Allergol Clin Immunol 2003 13 : 238 43.
7. Boushey HA, Sorkness CA, King TS et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005 352 : 1519 28.
8. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999 340 : 197 206.
9. Parameswaran K, Watson R, Gauvreau GM, Sehmi R, O'Byrne PM. The effect of pranlukast on allergen-induced bone marrow eosinophilopoiesis in subjects with asthma. Am J Respir Crit Care Med 2004 169 : 915 20.
10. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6 to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005 116 : 360 9.
11. Zeiger RS, Szefler SJ, Phillips BR et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006 117 : 45 52.
12. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002 109 : 68 74.
13. Westbroek J, Pasma HR. Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Respir Med 2000 94 : 112 8.
14. Yurdakul AS, Taci N, Eren A, Sipit T. Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 2003 97 : 1313 9.
15. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment fro asthma in children. Cochrane Database Syst Rev 2006 1 : CD002885.
16. O'Byrne PM, Barnes PJ, Rodrigeuz-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001 164 : 1392 7.
17. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults. Cochrane Database Syst Rev 2005 2 : CD005307.
18. Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003 58 : 204 11.
19. Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003 58 : 211 6.
20. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006 4 : CD003137.
21. Greenstone IR, NiChroinin MN, Masse V et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005 94 : CD005533.
22. Haahtela T, Tamminen K, Malmberg LP et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006 28 : 748 55.